share_log

HC Wainwright & Co.:维持康乃德生物医药(CNTB.US)评级,由买入调整至买入评级, 目标价由7.00美元调整至8.00美元。

HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.

Zhitong Finance ·  Apr 17 18:40
HC Wainwright & Co. : The rating of Conrad Biopharmaceuticals (CNTB.US) was maintained, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $8.00.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment